Eric Wombwell – PESI – Pharmacology of Infectious Disease: Essential Elements for an Impactful Clinical Pharmacy Practice

Description

Eric Wombwell – PESI – Pharmacology of Infectious Disease: Essential Elements for an Impactful Clinical Pharmacy Practice download, Eric Wombwell – PESI – Pharmacology of Infectious Disease: Essential Elements for an Impactful Clinical Pharmacy Practice review, Eric Wombwell – PESI – Pharmacology of Infectious Disease: Essential Elements for an Impactful Clinical Pharmacy Practice free

Eric Wombwell – PESI – Pharmacology of Infectious Disease: Essential Elements for an Impactful Clinical Pharmacy Practice

Dr. Eric Wombwell, PharmD, and Board Certified Infectious Disease Pharmacist will be your guide in this seminar, as you learn the latest evidence in the pharmacology of infectious diseases and application of this evidence to enhance your clinical pharmacy practice.

With new antibiotics, vaccines, treatment guidelines, and evidence-based research continuously becoming available, the need to stay up-to-date is an imperative for pharmacists.  The CDC recommends that pharmacists receive ongoing education about a variety of areas, including adverse reactions to antibiotics, antibiotic resistance and optimal prescribing.

Dr. Wombwell will draw attention to clinical situations where antibiotics are overprescribed, unnecessarily used, and underutilized in the treatment of infections. He will provide approaches to improve antibiotic use in these situations—resulting in reduced antibiotic cost, resistance, and collateral damage, improving patient outcomes in both outpatient and inpatient environments.

You’ll leave with the knowledge and strategies to:

• Integrate current, best-practice treatment guidelines
• Limit adverse reactions from antibiotics
• Implement antimicrobial de-escalation strategies
• And more!

The need for robust antibiotic stewardship has never been more pressing.

Speaker

Eric Wombwell, PharmD, BCIDP

Dr. Eric Wombwell is a board-certified infectious diseases pharmacist and clinical associate professor for the Department of Pharmacy Practice and Administration at the University of Missouri – Kansas City, School of Pharmacy. Eric completed his PharmD degree at the University of Missouri Kansas City, followed by an ASHP accredited pharmacy practice residency at the Kansas City VA Medical Center. Following residency, he accepted a full-time non-tenured clinical faculty position at the University of Missouri – Kansas City, School of Pharmacy. His teaching responsibilities include infectious diseases topics throughout the curriculum. Eric also has a clinical appointment at Centerpoint Medical Center rounding with the infectious diseases consult team and supporting antimicrobial stewardship efforts at the facility.

Eric is regularly published in pharmacy and infectious diseases research and is frequently invited to deliver continuing education presentations locally and nationally to various health-professional audiences. He is recognized for excellence in teaching through various awards, including the “Missouri Pharmacist Association – UMKC Faculty Member of the Year”, and the “University of Missouri – Kansas City Provost’s Award for Excellence in Teaching”.

Speaker Disclosures:
Financial: Eric Wombwell has an employment relationship with the University of Missouri. He receives a speaking honorarium, recording royalties, and a consulting fee from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Eric Wombwell is a member of the Society of Infectious Diseases Pharmacists, the Missouri Pharmacists Association, American Association of Colleges of Pharmacy, Infectious Diseases Society of America, and Centerpoint Medical Center.

Objectives

1. Develop antibiotic recommendations in response to microbiologic testing results.
2. Describe clinical scenarios compelling for empiric coverage of resistant bacteria.
3. Discriminate clinical scenarios requiring initiation of antibiotics.
4. Choose appropriate risk factor–based empiric antibiotic regimens for acute infections.
5. Recognize clinical scenarios necessitating avoidance of specific antibiotics based on side effect profiles.
6. Identify clinical situations appropriate for newly approved antimicrobials.

Outline

Considerations for Successful Empiric Therapy

• Spectrum of activity for commonly used antibiotics
• Normal flora for infectious sites
• Resistance associated with common bacteria
• Pharmacodynamic influences on antibiotic dosing

Interpretation of Microbiologic Test Results 

• Gram stain results
• Culture and sensitivity results
• Minimum inhibitory concentration (MIC) evaluation
• PCR results

Antibacterial Resistance

• Trends
• Mechanisms of resistance
• Contributing factors
• Antibiotic stewardship concepts

Antibiotic Related Allergies– Penicillin and ‘Sulfa’

• Define true allergy versus side effect
• Penicillin allergy and cephalosporin cross sensitivity
• ‘Sulfa’ allergy

SARS-CoV-2

• Clinical trial data for therapeutics
• Clinical trial data for vaccines

Skin and Soft Tissue Infections

• Streptococcus pyogenes vs. MRSA
• Evidence for antibiotic management
• IDSA treatment guidelines
• Vancomycin AUC/MIC monitoring

Pneumonia

• Evidence for pathogen etiology
• Evidence for antibiotic management
• IDSA/ATS community-acquired pneumonia treatment guidelines
• Resistance risk factors and management
• IDSA/ATS hospital- and ventilator-acquired pneumonia treatment guidelines
• New antibiotics for MDR infections

Influenza

• Evidence on vaccine timing and use in older adults
• Clinical trial data for therapeutics
• IDSA/CDC treatment guidelines

Urinary Tract Infections

• Resistance trends
• Clinical trial data for therapeutics
• Antibiotics for MDR infections

Clostridium Difficile Infection

• Risk factor literature review
• Compare antibiotic risk levels
• IDSA treatment guidelines
• Clinical trial data for therapeutics
• Probiotics prophylaxis evidence review

Target Audience

Inpatient and outpatient pharmacists engaged in review of antimicrobial prescription orders. In particular, those pharmacists interested in obtaining further antimicrobial expertise to aid in the care of patients with infectious diseases through optimal antimicrobial drug choice, route, dose, and duration of use.

Frequently Asked Questions:

1. Innovative Business Model:
   • Embrace the reality of a genuine business! Our approach involves forming a group buy, where we collectively share the costs among members. Using these funds, we purchase sought-after courses from sale pages and make them accessible to individuals facing financial constraints. Despite potential reservations from the authors, our customers appreciate the affordability and accessibility we provide.
2. The Legal Landscape: Yes and No:
   • The legality of our operations falls into a gray area. While we lack explicit approval from the course authors for resale, there’s a technicality at play. When procuring the course, the author didn’t specify any restrictions on resale. This legal nuance presents both an opportunity for us and a boon for those seeking budget-friendly access.
3. Quality Assurance: Unveiling the Real Deal:
   • Delving into the heart of the matter – quality. Acquiring the course directly from the sale page ensures that all documents and materials are identical to those obtained through conventional means. However, our differentiator lies in going beyond personal study; we take an extra step by reselling. It’s important to note that we are not the official course providers, meaning certain premium services aren’t included in our package:
     • No coaching calls or scheduled sessions with the author.
     • No access to the author’s private Facebook group or web portal.
     • No entry to the author’s exclusive membership forum.
     • No direct email support from the author or their team.

   We operate independently, aiming to bridge the affordability gap without the additional services offered by official course channels. Your understanding of our unique approach is greatly appreciated.

Refund is acceptable:

• Firstly, item is not as explained
• Secondly, Item do not work the way it should.
• Thirdly, and most importantly, support extension can not be used.

Thank you for choosing us! We’re so happy that you feel comfortable enough with us to forward your business here.